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Purpose: Robotic liver surgery (RLS) is becoming more
popular as an alternative to laparoscopic liver surgery.
Recently, several centers have started with RLS but data on
both implementation and outcomes of RLS are still scarce.
This study aims to report on the initial experience with RLS
in two centers of the HPB-Amsterdam network.
Methods: Retrospective study in two sites of the HPB-
Amsterdam network (Amsterdam UMC, location AMC
and OLVG) on consecutive patients after elective RLS for
all indications (December 2018 - January 2021). Selection
criteria for RLS were tumors<10cm in size without contact
with the central portal or caval veins. Primary outcome was
the rate of major morbidity (ClavieneDindo grade III).
Operative outcomes were stratified for the first and last 50
RLS procedures.
Results: Overall, 100 RLS procedures were performed by
teams from four HPB-surgeons, including 52 minor, 40
technically major and 7 anatomically major RLS. Median
operative time was 143 (IQR 101-210) minutes and median
blood loss was 150 (IQR 50-400) mL. The conversion rate
was 3.0% (n=3). The rate of major morbidity was 4.0%
(n=4). Median length of hospital stay was 3 (IQR 2-4) days.
The rate of R0 resection was 80.6% (n=58). The 30-day/in-
hospital mortality was 1.0% (n=1).
Stratification into two groups of 50 procedures found no
difference in blood loss and conversion rate with less major
morbidity in the second 50 RLS procedures as compared to
the first 50.HPB 2021, 23 (S3), S674eS751Conclusion: This initial experience of 100 robotic
liver resections in the HPB-Amsterdam network dem-
onstrates a safe implementation. Future studies need to
determine the proficiency learning curve and determine
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Introduction: Major liver resections in patients with a
small Future Liver Remnant (FLR) can only be
performed safely after induction of adequate FLR-hy-
pertrophy to reduce the risk of post-hepatectomy liver
failure (PHLF). Hypertrophy induced by Portal Vein
Embolization (PVE) is slow and 20-30% of patients are
not resected after this procedure. Combining Portal and
Hepatic Vein Embolization (PVE/HVE) accelerates FLR
hypertrophy, whether this increases resectability is stud-
ied in this analysis.
Methods: All participating centers in the DRAGON
COLLABORATIVE that had already performed >5 PVE/
HVE between 2016 and 2019 were asked to contribute
cases of PVE/HVE or PVE. Osirix MD was used for
volumetric assessment. Multivariable analysis was
performed for the endpoints: resectability, FLR hypertro-
phy, and major complications (Clavien-Dindo >IIIA).
Results: From 7 DRAGON centers, 39 PVE/HVE and 160
PVE cases were included.
After PVE/HVE, resectability (90% vs. 68%, p=0.007)
and FLR hypertrophy (59% vs. 48%, p=0.02) were higher
than PVE alone. 90-day mortality (3% vs. 16%, p=0.15)
and major complications (26% vs. 34%, p=0.55) did not
significantly differ between groups.
S716 FREE PAPER SESSIONS (FP01-FP20) - ORALSPVE/HVE was not a significant risk factor for major
complications, but it was an independent predictor for
survival and hypertrophy. Results were confirmed via
multivariable analysis.
Conclusion: PVE/HVE resulted in increased resec-
tablity and liver growth compared to PVE alone.
Complications and mortality rate did not differ between
PVE/HVE and PVE. Superiority of PVE/HVE over
PVE will be investigated in the prospective DRAGON
trials.FP11.03
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Purpose: Perioperative liver function evaluation with
indocyanine green (ICG) has been widely used in Asian
countries. This study aims to review current strategies for
postoperative liver failure (PLF) assessment with ICG in
patients undergoing hepatectomy or liver transplant.
Method: A systematic review was performed according to
PRISMA guidelines. PubMed, Scopus, WoS, and
Cochrane Library were searched up to 2021. The primary
outcome measure was PLF. As a secondary outcome, major
postoperative complications defined by Clavien-Dindo III-
V grades were assessed. Quantitative analysis by random-
effects model was performed for studies reporting similar
methods.
Results: This is the first systematic review to date. Out of
1674 studies, 40 were included in the review. Most were
prospective studies (21/40) from Asia (23/40). Of the 31
studies including hepatectomies, only 15 reported PLF by
ISGLS criteria. 94% of studies used ICG preoperatively,
though some combined intraoperative and/or postoperative
use. 77% of them obtained significant results and recom-
mended its use. For liver resection, preoperative ICG-
R15>15% was the most frequent cut-off related to PLF.
For liver transplant, early postoperative ICG-PDR<12%/
min was generally related to worse outcomes. Meta-anal-
ysis was performed over 4 studies including 478 patients
undergoing hepatectomy for hepatocarcinoma. The pooled
MD of ICG-R15 between patients with and without PLF
was 0.59 (95% CI: 0.16-1.03; I2=64%). Finally, 3 studies
reporting complications after hepatectomy by ICG-R15
cut-off were assessed. No significant association between
ICG-R15 and major complications (OR 0.8; 95% CI: 0.47 -
1.35; I2=83%) was found.
Conclusion: Literature suggests ICG clearance is a useful
non-invasive method to predict PLF in liver surgery.However, due to different parameters and variable usage
methods across studies, a global consensus should be
defined.Figure 1. Forest plots.FP11.04
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Purpose: "Associating Liver Partition and Portal Vein
Ligation for Staged Hepatectomy" (ALPPS) and "Portal
Vein Embolization" (PVE) have an important role in the
treatment of malignant liver tumors. Both procedures
induce rapid and effective hypertrophy of the future liver
remnant (FLR) to prevent postoperative liver failure. The
aim of this study is to determine impact factors on the ki-
netic growth rate (KGR) and subsequently FLR, in terms of
complications, posthepatectomy liver failure (PHLF) and
survival.
Method: Patients undergoing ALPPS and PVE from
2010 until 2020 were included. KGR was defined as
the quotient of hypertrophy and the time interval in
weeks between intervention (PVE/ALPPS step 1) and
resection.
Results: Overall, 90 patients underwent ALPPS and 82
patients received PVE. The association between KGR
and PHLF indicates a significant nonlinear effect in PVE
(p=0.009) and ALPPS (p=0.05). For ALPPS, the inci-
dence of PHLF significantly decreased from 30% to 8%
(p=0,032) at cutoff value of KGR of >7 %/week. Pa-
tients with a KGR of >7%/week had a higher preoper-
ative skeletal muscle index (p=0,029), but the same body
mass index (p=0,301). Tumor anemia showed an asso-
ciation with a reduction of KGR (p=0,159). However,
the KGR had no effect on postoperative morbidity,HPB 2021, 23 (S3), S674eS751
